Positive topline results from pivotal XTEND-Kids phase 3 study of efanesoctocog alfa in children under 12 years of age with haemophilia A
Primary endpoint was met with no factor VIII inhibitors detected, confirming the safety profile of efanesoctocog alfa in previously treated patients under 12 years of age The completion of XTEND-Kids represents the final milestone needed for regulatory submission in the EU Sobi® and Sanofi today announced that the XTEND-Kids phase 3 pivotal study evaluating the safety, efficacy and pharmacokinetics of efanesoctocog alfa as once-weekly prophylaxis in previously treated patients under 12 years of age with severe haemophilia A met its primary endpoint. No factor VIII inhibitors